Q1 EPS Estimate for Artiva Biotherapeutics Lifted by Analyst

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Investment analysts at HC Wainwright boosted their Q1 2025 EPS estimates for shares of Artiva Biotherapeutics in a research report issued to clients and investors on Wednesday, March 26th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($0.68) per share for the quarter, up from their prior forecast of ($0.76). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics' Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.89) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($4.10) EPS.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC restated a "buy" rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Tuesday, March 25th. Cantor Fitzgerald dropped their price objective on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, March 25th. Finally, Wedbush restated an "outperform" rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $20.40.

Artiva Biotherapeutics Trading Up 2.7 %

NASDAQ:ARTV traded up $0.08 during mid-day trading on Friday, hitting $3.08. 16,021 shares of the company's stock traded hands, compared to its average volume of 113,332. The company has a fifty day moving average of $4.64 and a 200 day moving average of $9.14. Artiva Biotherapeutics has a twelve month low of $2.92 and a twelve month high of $17.31.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth about $42,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Artiva Biotherapeutics in the fourth quarter valued at approximately $52,000. Wells Fargo & Company MN raised its stake in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company's stock worth $87,000 after buying an additional 3,361 shares during the period. MetLife Investment Management LLC purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at approximately $135,000. Finally, JPMorgan Chase & Co. acquired a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $166,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.